Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of chloroquine in the preparation of anti-herpes virus medicine

A technology of herpes virus and chloroquine, which is applied in the field of application of chloroquine to gamma-herpes virus and related diseases, and can solve the problems of vaccine research and development stage and the absence of anti-gamma-herpes virus drugs

Inactive Publication Date: 2017-04-19
SUN YAT SEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far there is no specific anti-gamma-herpes virus drug, and the vaccine is still in the research and development stage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chloroquine in the preparation of anti-herpes virus medicine
  • Application of chloroquine in the preparation of anti-herpes virus medicine
  • Application of chloroquine in the preparation of anti-herpes virus medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 1. Take well-grown BCBL1 cells and inoculate them in 6-well transparent flat-bottomed plates, 2×10 per well 6 Cells were divided into induced group and non-induced group. The medium used is a complete medium: high-glucose DMEM, 10% fetal bovine serum and 1% double antibody, and the culture condition is 5% carbon dioxide, 37°C;

[0025] 2. After 3 hours, the induction group was added with inducer TPA, the final concentration was 20ng / mL;

[0026] 3. Chloroquine was added after 3 hours of induction, and the final concentrations were 0 μM, 5 μM, 10 μM, 15 μM, and 20 μM;

[0027] 4. After adding the drug, culture for 48 hours, harvest the cells at 1000 rpm, and 10 minutes;

[0028] 5. Carry out Western blot experiments, the results are as follows: figure 1 It was shown that the expression of KSHV-related proteins RTA, ORF45, K8, and ORF64 in BCBL1 cells was inhibited by chloroquine after 3 hours of induction, and the inhibitory effect was concentration-dependent. This s...

Embodiment 2

[0030] 1. Take well-grown iSLK-219 cells, inoculate them in 6-well transparent flat-bottomed plates at a ratio of 1:4, and divide the cells into induced and non-induced groups.

[0031] 2. After 12 hours, the cells adhered to the wall, and the induction group was added with inducers Dox and NaB, the final concentrations were 1 μg / mL and 0.3 μM, respectively;

[0032] 3. Chloroquine was added after 3 hours of induction, and the final concentrations were 0 μM, 2 μM, 5 μM, 8 μM, 10 μM, 15 μM, 20 μM, and 25 μM;

[0033] 4. After adding the drug for 48 hours, scrape the cells out of the plate with a cell scraper, rinse with cold PBS, collect the cells by centrifugation at 1000rpm, 10min, and 4°C;

[0034] 5. Carry out western blot experiment, the experimental results are as follows: figure 2 Shown: the expression of KSHV-related proteins RTA, ORF45, and K8 in iSLK-219 cells was inhibited by chloroquine, and the inhibitory effect was concentration-dependent.

Embodiment 3

[0036] 1. Take the well-growing cell line BCBL1 and plant it in a 48-well plate. The amount of cells used is 1×10 5 / hole, the cells are divided into non-induced group (3 holes) and induction group (15 holes);

[0037] 2. After 3 hours, the induction group was added with inducer TPA, the final concentration was 20ng / mL;

[0038] 3. After 3 hours of induction, add corresponding concentrations of chloroquine, with concentrations of 0 μM, 5 μM, 10 μM, 15 μM, and 20 μM, respectively, with 3 wells for each concentration;

[0039] 4. Harvest the cells after 96 hours, weigh 10,000 g, and take the supernatant at 4°C;

[0040] 5. Extract extracellular viral DNA, the method is as follows:

[0041] a. Take 200 μL supernatant, add 2 μL DNase I, 20 μL 10×DNase I buffer, and incubate in a 37°C incubator for 1 hour;

[0042] b. Add 10 μL of 0.5M EDTA to the above liquid, mix well, and terminate the reaction;

[0043] c. Inactivate in a water bath at 80°C for 10 minutes;

[0044] d. Add...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of autophagy inhibitors, namely chloroquine, to medicines for treating herpesvirus, in particular to herpesvirus related to Kaposi's sarcoma and EB virus. The chloroquine has the good inhibiting effect on the two kinds of virus; a powerful theoretical basis and a powerful practice basis are provided for further researches and further developments of the anti-herpesvirus medicines; and the important researching and developing values and the important development significance are achieved.

Description

technical field [0001] The invention relates to a new application of chloroquine, an autophagy response inhibitory drug, in medicine, and more specifically, relates to the application of chloroquine to gamma-herpes virus and related diseases. Background technique [0002] Kaposi's sarcoma-associated herpesvirus KSHV (Kaposi's sarcoma-associated herpesvirus) infection-induced Kaposi's sarcoma KS is a common malignant tumor in AIDS patients, about 20% of AIDS patients will be accompanied by Kaposi's sarcoma, and AIDS- The mortality rate of KS patients is extremely high, and its 5-year survival rate is only about 8%. In the normal population, more than 95% of individuals with KSHV infection do not show clinical symptoms and become ill. However, in immunosuppressed patients, such as AIDS patients, organ transplant patients, and chemotherapy and radiotherapy patients, KSHV has a high infection rate and great harm. Infection can lead to Kaposi's sarcoma (KS), primary infiltration...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/47A61P31/22
CPCA61K31/4706
Inventor 况二胜杨梦甜黄璐
Owner SUN YAT SEN UNIV